Oppenheimer Reiterates Outperform on Perspective Therapeutics, Adjusts Target to $19 from $2 (10-for-1 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Perspective Therapeutics (AMEX:CATX) and adjusted the price target to $19 from $2, following a 10-for-1 reverse stock split.
June 18, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reiterated an Outperform rating on Perspective Therapeutics and adjusted the price target to $19 from $2, following a 10-for-1 reverse stock split.
The reiteration of an Outperform rating and a significant adjustment in the price target from $2 to $19 by a reputable analyst like Oppenheimer is likely to positively impact the stock price of Perspective Therapeutics in the short term. The 10-for-1 reverse stock split also indicates a strategic move to increase the stock's marketability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100